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binations of curettage, shave, and cautery 
(the lesions weren’t diff erentiated by removal 
method or location). Investigators didn’t re-
port on residual scarring with any method. 
However, expert opinion states that surgical 
excision often results in a conspicuous linear 
scar.2
Surgery vs laser therapy or no treatment
Another retrospective cohort study described 
treatment, recurrence rate, residual scarring, 
and patient satisfaction in 76 patients with 
pyogenic granuloma (mean age 6 years; range 
4 months to 17 years). Outcomes were as-
sessed by telephone follow-up.3 
Fifty-eight lesions were removed by surgi-
cal excision and cautery with no recurrences 
(55% of patients had subtle scarring). Nine le-
sions were treated with pulsed dye laser (33% 
recurrence, 44% subtle scarring); 3 lesions 
were removed by CO2 laser (100% recurrence, 
33% subtle scarring). Four patients were fol-
lowed but not treated (no explanation given); 
all untreated pyogenic granulomas disap-
peared spontaneously within 6 to 18 months 
with no recurrences; 1 patient had subtle 
scarring. 
 What’s the best treatment 
for pyogenic granuloma?
Evidence summary
Little evidence directly compares treatments 
for pyogenic granuloma. Most studies ex-
amine multiple treatment methods without 
comparing results statistically, combine data 
from adults and children, or comprise case 
series using a single treatment method. Th e 
TABLE summarizes outcomes for diff erent 
therapies.
Surgical excision: Low recurrence, 
but scarring is common
A retrospective cohort study audited recur-
rence rates in 408 patients (mean age 41 years, 
range 5 months to 90 years) whose pyogenic 
granulomas were treated with either surgical 
excision or combinations of curettage, shave, 
and cautery.1 Investigators identifi ed cases 
of histopathologically confi rmed pyogenic 
granuloma over a 10-year period from a hos-
pital database. Th irty-six percent of granu-
lomas were located on the head and neck, 
33% on the arm, 15% on the trunk, and 8% on 
the leg. 
Of 326 lesions treated with surgical exci-
sion, 4 (3.7%) recurred. Th e overall recurrence 
rate was 10.3% for 82 lesions removed by com-
EVIDENCE-BASED ANSWER
A it’s difficult to say which  treatment is best, since most studies 
don’t compare treatments directly. Pros and 
cons vary. Simple surgical excision is asso-
ciated with a low risk of recurrence, but of-
ten leaves a visible scar. Curettage or shave 
excision, with cautery, is more likely to suc-
ceed in 1 session than cryotherapy; both 
may leave a smaller scar than surgery. Laser 
therapy, which may require multiple ses-
sions, and sclerotherapy may be least likely 
to cause visible scarring (strength of recom-
mendation [SOR]: C, small cohort studies 
and case series). 
Untreated pyogenic granulomas re-
gress spontaneously within 6 to 18 months 
with some risk of scarring (SOR: C, a subset 
of patients in a retrospective cohort study).
Ari Gilmore, MD; 
Gary Kelsberg, MD; 
Sarah Safranek, MLS
Valley Family Medicine, 
Renton, Wash (Drs. Gilmore 
and Kelsberg); and University 
of Washington Health Sciences 
Library, Seattle (Ms. Safranek)
Simple surgical 
excision is 
associated with 
a low risk of 
recurrence but 
often leaves a 
visible scar.
40_JFP0110   40 12/21/09   12:05:20 PM
41JFPONLINE.COM VOL 59, NO 1  |  JANUARY 2010  |  THE JOURNAL OF FAMILY PRACTICE
TK
Cryotherapy may require 
more treatments than curettage
A prospective trial randomized 89 patients 
(mean age 34 years; range 11-88 years) with 
pyogenic granulomas that were 1.5 cm or 
smaller to receive either curettage or cryother-
apy, then evaluated the number of treatments 
required and whether scarring occurred. 
Follow-up was 85%.4 
A single curettage resolved pyogenic 
granuloma in 35 of 36 patients (97%); 9 of 
the 36 patients (31%) had residual scarring. 
Twenty-fi ve of 40 pyogenic granulomas (63%) 
responded to 1 cryotherapy treatment, 13 le-
sions (32%) resolved after 2 treatments, and 
2 (5%) resolved after 3 treatments; 17 of the 
40 patients (42.5%) had a residual scar. Curettage 
required fewer treatments overall than cryothera-
py (P<.001), but no signifi cant diff erence in resid-
ual scarring was noted between the 2 treatments.
A case series reported on 135 patients 
(mean age 26 years; range 4 months to 
70 years) whose pyogenic granulomas were 
treated with cryotherapy.5 Seventy-eight (58%) 
had complete resolution with 1 session, 30% 
needed 2 sessions, 8% needed 3 sessions, and 
5% needed 4 sessions (mean 1.58 sessions). 
Ninety-four percent had an excellent cosmet-
ic result (including 12% with a small fl at scar); 
5% had residual hypopigmentation.
CO2 laser usually removes 
lesions in 1 session 
Another case series of 100 patients (mean age 
27 years; range 6 months to 84 years) treated 
with CO2 laser reported that the pyogenic 
granuloma was removed completely in 1 ses-
sion in 98 patients. Twelve percent of patients 
had visible scarring and another 10% had 
slight textural skin changes. All patients re-
ported satisfaction with the results.6
Pulsed dye laser works for small lesions
A case series of 22 patients (mean age 
3.4 years; range 6 months to 16 years) treated 
with pulsed dye laser for mostly small lesions 
(average diameter 4 mm) on the face report-
ed successful removal in 20 children in 1 to 
6 treatment sessions (average 2.25) with no 
residual scarring. Two children with larger 
lesions required shave excision with cautery 
(scarring was not assessed).7
Sclerotherapy: 
No recurrence, inconspicuous scars
A case series reported results in 9 patients 
(median age 18 years; range 1-57 years) with 
pyogenic granuloma treated with a single in-
jection of the sclerosing agent monoethanol-
amine oleate.2 All lesions disappeared without 
recurrence; the authors described remaining 
TABLE
How treatment outcomes for pyogenic granuloma compare 
Treatment Studies Total patients
Treatment 
sessions Recurrence Scarring
Surgical excision 2 retrospective cohort studies1,3 384 1 0%-3.7% 55%
Curettage or 
shave excision 
with cautery
1 retrospective cohort study,1 
1 prospective cohort study4
118 1-2 
(average 1.03)
10% 31%
Cryotherapy 1 prospective cohort 
study,4 1 case series5
175 1-3 
(average 1.5)
Unknown 42%
CO2 laser 1 retrospective cohort 
study,3 1 case series6
103 1 2%-100% 12%-33%
Pulsed dye laser 1 retrospective cohort 
study,3 1 case series7 
31 1-6 
(average 2.25)
9%-33% 9%-44%
Sclerotherapy 1 case series2 9 1 0% “Inconspicuous”
Expectant 
management
1 retrospective cohort study3 4 None 0% 25%
41_JFP0110   41 12/21/09   12:05:24 PM
42 THE JOURNAL OF FAMILY PRACTICE  |   JANUARY 2010  |   VOL 59, NO 1
scars as inconspicuous. One patient reported 
residual pain lasting 4 weeks after injection 
of the sclerosing agent into a 1.5 cm × 1.0 cm 
pyogenic granuloma that hadn’t responded to 
previous cryotherapy.
Recommendations
A standard dermatology textbook recommends 
curettage with cautery, and reports that sponta-
neous regression is common after 6 months.8 A 
standard pediatric textbook recommends sur-
gical excision with or without cautery, adding 
that small pyogenic granuloma lesions (<5 mm) 
may be removed with pulsed dye laser.9
An online textbook recommends either 
excision or shave (with or without curettage), 
but advises surgical excision with histologic 
confi rmation for pyogenic granuloma lesions 
that can’t be diff erentiated with certainty from 
amelanotic melanoma, which typically grows 
more slowly.10 
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